Creating Pathways to Impact
The University of Oklahoma is a driving force in economic impact, providing tools and resources for commercializing innovation, and preparing the next generation of citizen leaders of our state and nation for success in a knowledge-based global society.
The Office of Technology Commercialization (OTC) supports university researchers in protecting their intellectual property, and works with industry to find the best path to the commercial marketplace, including playing a critical role working with Oklahoma-based start-ups that spin out of OU.
In the last 20 years, OTC has evaluated more than 1,500 pieces of innovation, filed more than 2,200 patents, licensed 170 technologies, and launched 35 companies.
OU Research In Action
When heavy rainfall and flooding trapped a Thai boys’ soccer team in a cave during the summer of 2018, Norman-based Weather Decision Technologies (WDT) was enlisted to aid in the rescue. Experts in weather risk mitigation, WDT used weather forecast software developed through OU’s Cooperative Institute for Mesoscale Meteorological Studies and licensed from OU to provide rescuers accurate rainfall predictions to plan critical mission timing.
University Spin-Out Selexys Acquired by Novartis
In late 2016, Novartis announced its up to $665 million acquisition of Selexys Pharmaceuticals Corp., a start-up developed by three OU faculty members and based on OU Health Sciences Center research in inflammatory diseases.
Pure Protein Partners with AbbVie
Pure Protein, a portfolio company of Emergent Technologies, Inc., began a research and license agreement with AbbVie biopharmeceuticals in January 2017. This partnership will facilitate the further development of innovative immunooncology therapies to help fight cancer.
"OU provides a tremendous environment that encourages academic growth and innovation. OTC has positioned itself to equitably evaluate new OU technology and to move the most promising technology forward for the benefit of mankind."
- Dr. William Hildebrand, Chief Scientist & OU Professor of Microbiology & Immunology
Moleculera Labs Improves Lives
Using The Cunningham Panel™, Oklahoma City-based Moleculera Labs is improving the lives of children and families across the nation. The panel, which is based on the research of OU Health Sciences Center Professor of Microbiology & Immunology Dr. Madeleine Cunningham, identifies infection-induced autoimmune neuropsychiatric disorders such as PANS and PANDAS – an important step in families seeking effective treatment.
According to Moleculera Labs, neuropsychiatric disorders are those illnesses that have both neurological and psychiatric features. Millions of children and adolescents in the United States are impacted by a mental health condition. In fact, more than 17 million children in the U.S. currently have or have had a psychiatric disorder.* That’s more than all pediatric cases of cancer, diabetes, and AIDS combined.
*Source: Child Mind Institute, Children’s Mental Health Report, 2015
Moving Innovation Closer to the Market
Growth Fund
An initiative to spark University innovation, the Office of Technology Commercializationt’s Growth Fund strengthens the commercial potential of University research and intellectual property by providing short-term funding for commercially-focused research and prototyping.
Available to all faculty, staff, and graduate students on OU’s three campuses, this program allows researchers to bridge the gap between academia and industry by providing up to $75,000 in funding to answer market-driven questions. The competitive process requires applicants to provide market feedback, demonstrate a need/demand for the innovation, outline a path to commercialization, and “pitch” the plan to a committee of research and entrepreneurship experts.
Over the last seven years, we've reinvested over $850,000 into translational research to help promising innovation reach the market.
